Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:10/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the sixth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of dirucotide (MBP8298) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of dirucotide (MBP8298) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... foam of atom-thick sheets can be made to any ... Rice University. , In microscopic images, the foam ... and walls that reinforce each other. The structure consists ... of graphene oxide that self-assemble with the assistance of ... the foam could find use in structural components, as ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation (IMCL) ... medicine, treatment of infectious diseases as well as ... and prevention of pathologies like cardiovascular disease, Alzheimer,s ... 2014, ImmunoClin Corporation will complete the strategic relocation ... D.C. , a key center of North ...
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... and energy use, increased its investment in Green Chemistry ... around the world last year, the Company announced Monday ... if Science Changed the World? The ... several honors for being a responsible corporate citizen, including ...
Breaking Biology Technology:Tough foam from tiny sheets 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... 2011 BioStorage Technologies, Inc. a global provider ... cold chain logistics for the bioscience industry, will ... the International Contract Services Expo (ICSE), on Wednesday, ... The symposium will include two 1-hour presentations ...
... International, Inc. (OTC Pink: DYAI), a global biotechnology ... financial results for the third quarter ended September ... to discuss those financial results as follows: ...  After market close, Thursday, November 3, 2011. ...
... 2011 Verenium Corporation (Nasdaq: VRNM ), ... enzymes, today announced that it has entered into an ... the United States ("Ex-Im Bank") for two 18-month, secured ... These new credit facilities will allow the ...
Cached Biology Technology:BioStorage Technologies to Host Global Sample Management Benchmarking Symposium at International Contract Services Expo 2Verenium Announces Up to $16 Million in New Secured Financings 2Verenium Announces Up to $16 Million in New Secured Financings 3
(Date:7/28/2014)... Roald Amundsen reached the South Pole in 1911, but ... before any human. , Using data from 16 ice ... continent, including the South Pole, a group led by ... Reno, Nevada, created the most accurate and precise reconstruction ... The new record, described in an article published today ...
(Date:7/28/2014)... among minerals and organic compounds in hydrothermal environments are ... provide energy for the deep biosphere, and may have ... is known about how minerals influence organic reactions. ... demonstrated how a common mineral acts as a catalysts ... for toxic solvents or expensive reagents. , At the ...
(Date:7/28/2014)... of juvenile rat brain cells suggests that the effects ... between brain cells are temporary. , The study, published ... ONE , was conducted by biologists at the University ... in New York in response to concerns, arising from ... exposing children to general anesthetics may increase their susceptibility ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... UT Southwestern Medical Center have discovered a basic mechanism ... vessels can grow ?sometimes abnormally ?suggesting methods of treatment ... blood vessels is involved in hypertension, coronary artery disease, ... this detailed mechanism, it is now possible to begin ...
... line that produced humans seems to be among the slowest. ... the European Molecular Biology Laboratory (EMBL), is that our species ... been lost in more quickly-evolving animals. This overturns a commonly-held ... The work appears in the current issue of the journal ...
... willow warblers and beaver dams once were bountiful in an ... wolves left this area, elk grew more plentiful, browsing heavily ... and sparrows have replaced the warblers in what is now ... absence of the wolf, a top predator. That's the compelling ...
Cached Biology News:UT Southwestern researchers unravel control of growing blood vessels 2The earliest animals had human-like genes 2The earliest animals had human-like genes 3Wolves' top-down effect 2
... hydrolytic enzyme that catalyzes the conversion,of ... maltose, maltotriose and,dextrins. The level of ... human,body are of clinical importance,1-3 while ... for industry.4, The EnzChek Amylase Assay ...
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... FL is equipped with ... measurement technologies that complement ... advanced features of Fluoroskan ... Fluoroskan Ascent FL provides ...
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
Biology Products: